Sign up for alerts
Want to make sure you never miss the latest updates?
Insights with impact
Industry Insight
End of year reflections from our CEO
Industry Insight
Driving breakthroughs for myelofibrosis care
Industry Insight
What’s next for cambritaxestat?
Industry Insight
Realizing the potential of PI3Kδ inhibitors in peripheral T-cell lymphomas
Industry Insight
iOnctura expands roginolisib trials to the US
Industry Insight
iOnctura enhances board to accelerate growth and innovation
Industry Insight
Addressing drug resistance in non-small cell lung cancer
Industry Insight
Scientific innovation in uveal melanoma
Industry Insight
Opportunities and challenges in oncology immunotherapy
Industry Insight
Reflections from our CEO
Industry Insight
Pancreatic cancer – our commitment to scientific advances
Industry Insight
A bold new era in global cancer drug discovery
Industry Insight
A note from our CEO
Industry Insight
Realising the potential of autotaxin therapy in cancer
Industry Insight
PI3Kδ inhibitors offer serious promise in solid tumors
Industry Insight
Emerging therapies offer hope for uveal melanoma patients
Download our corporate deck
Find out more about our mission to give patients more momets that matter
All news
Press release
US FDA grants orphan drug designation for iOnctura’s first-in-class autotaxin cancer therapy
Press release
Updated clinical safety and efficacy data for iOnctura’s roginolisib presented at ESMO immuno-oncology congress 2023
Press release
iOnctura to present research on roginolisib and IOA-359 at ASH
Press release
iOnctura announces FDA clearance of IND application for roginolisib, a first-in-class allosteric modulator of PI3Kδ
Press release
New research highlights potential of iOnctura strategy combining autotaxin and TGF-β inhibitors in cancer
Press release
iOnctura to present research at leading scientific conferences in June 2023
Press release
Peer-reviewed translational research paves the way for first-in-class autotaxin inhibitor IOA-289 in cancer
Press release
iOnctura expands pipeline and receives development grant from Health Holland and KWF
Press release
iOnctura awarded UK’s MHRA innovation passport for entry into innovative licensing and access pathway (ILAP)
Press release
iOnctura announces publication of pioneering research describing the unique biological features of roginolisib
Press release
iOnctura provides development update on first-in-class semi-allosteric PI3Kδ inhibitor program
Press release
iOnctura awarded EUR17.5 million funding from the EIC accelerator for clinical development of novel pancreatic cancer therapy
Looking for media
resources?